A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer
NCT07123441
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
300
Enrollment
OTHER
Sponsor class
Conditions
Colorectal Cancer
Interventions
DRUG:
Bevacizumab,Irinotecan liposome (II),5-FU/LV
Sponsor
Sanjun Cai